Table 4. Clinicopathological characteristics of the PTC patients used in this study.
| Covariates | Entire TCGAdataset (n=492) | Trainingdataset (n=246) | Testing dataset(n=246) | P value | |
|---|---|---|---|---|---|
| Age | <45 | 225 (45.7%) | 121 (49.2%) | 104 (42.3%) | 0.148a |
| >=45 | 267 (54.3%) | 125 (50.8%) | 142 (57.7%) | ||
| Nodal involvement | With nodal involvement | 379 (77%) | 197 (80.1%) | 182 (74%) | |
| Without nodal involvement | 4 (0.8%) | 1 (0.4%) | 3 (1.2%) | 0.208 | |
| Unknown | 109 (22.2%) | 48 (19.5%) | 61 (24.8%) | ||
| Extrathyroid extension | None | 328 (66.7%) | 163 (66.3%) | 165 (67.1%) | b |
| Minimal (T3) | 130 (26.4%) | 67 (27.2%) | 63 (25.6%) | ||
| Moderate/advanced (T4a) | 17 (3.5%) | 8 (3.3%) | 9 (3.7%) | 0.837 | |
| Very advanced (T4b) | 1 (0.2%) | 1 (0.4%) | 0 (0%) | ||
| Unknown | 16 (3.3%) | 7 (2.8%) | 9 (3.7%) | ||
| Gender | Male | 132 (26.8%) | 69 (28%) | 63 (25.6%) | 0.611b |
| Female | 360 (73.2%) | 177 (72%) | 183 (74.4%) | ||
| Disease free status | With tumor | 40 (8.1%) | 20 (8.1%) | 20 (8.1%) | b |
| Tumor-free | 442 (89.8%) | 223 (90.7%) | 219 (89%) | 0.441 | |
| Unknown | 10 (2%) | 3 (1.2%) | 7 (2.8%) | ||
| Pathologic stage | Stage I | 331 (67.3%) | 172 (69.9%) | 159 (64.6%) | b |
| Stage II | 50 (10.2%) | 20 (8.1%) | 30 (12.2%) | ||
| Stage III | 107 (21.7%) | 51 (20.7%) | 56 (22.8) | 0.315 | |
| Stage IV | 2 (0.4%) | 2 (0.8%) | 0 (0) | ||
| Unknown | 2 (0.4%) | 1 (0.4%) | 1 (0.4%) | ||
| Histological type | Other, specify | 7 (1.4%) | 3 (1.2%) | 4 (1.6%) | 0.421b |
| Classical/usual | 349 (70.9%) | 177 (72%) | 172 (69.9%) | ||
| Follicular | 101 (20.5%) | 45 (18.3%) | 56 (22.8%) | ||
| Tall cell | 35 (7.1%) | 21 (8.5%) | 14 (5.7%) | ||
| Vital status | Alive | 476 (96.7%) | 240 (97.6%) | 236 (95.9%) | 0.446b |
| Dead | 16 (3.2%) | 6 (2.4%) | 10 (4.1) |
aStudent's t-test
bChi square test